Rhonda Stamey, APRN, is a key member of the Advanced Therapy Center Medical Team at First Urology, where she plays an active role in advancing the treatment of prostate cancer. She provides expert ...

A. Lenore Ackerman, MD, PhD, discusses the renewed emphasis on symptom resolution over microbial eradication in the new AUA guideline for recurrent uUTI in women. The American Urological Association, ...

John P. Sfakianos, MD, discusses the significance of urine-based biomarkers for intermediate-risk patients and outlines key findings from the STRATA study. In February 2025, the American Urological ...

Apolo emphasized the value of having robust monotherapy data before advancing into combination strategies. Apolo emphasized the value of having robust monotherapy data before advancing into ...

AB001 is a novel PSMA-targeted radioligand therapy designed to treat metastatic prostate cancer with potentially higher tumor dose rates and lower normal tissue toxicity. The phase 1 trial will enroll ...

FGFR inhibitors are vital in bladder cancer treatment but face challenges due to significant toxicities, limiting long-term use. Dabogratinib selectively targets FGFR3, aiming to reduce toxicities ...

A new analysis supports return to widespread screening. A reevaluation of the tradeoffs of prostate cancer screening using the most recent data should rewrite the negative narrative associated with ...

Cycling has multiple benefits, and steps can be taken to prevent genitourinary injury. Bicycling across the globe is increasing as a means of exercise and transportation. Clinicians need to be ...

Novel therapies are promising but face questions about patient selection and efficacy. Erectile dysfunction is a common concern among aging males. Not only does ED affect quality of life, but it is ...

Although low, men experienced a higher risk for erectile dysfunction and hypogonadism after being prescribed semaglutide for weight loss; however, further questions remain. Non-diabetic men treated ...

The updated guideline includes 25 recommendations, emphasizing risk stratification and minimizing unnecessary evaluations for low-risk patients. New guidance incorporates urine-based tumor markers for ...

"We've been doing a lot of work at Johns Hopkins using high-dose testosterone therapies to treat patients with metastatic prostate cancer," says Mark C. Markowski, MD, PhD. In this interview, Mark C.